Erschienen in:
Open Access
01.12.2019 | Correction
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
verfasst von:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Erschienen in:
BMC Cancer
|
Ausgabe 1/2019
Correction to: BMC Cancer
DOI 10.1186/s12885-017-3286-5
Following publication of the original article [
1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:
Fig. 1 Swimlane plot of time to response, treatment duration, and duration of follow-up for efficacy-evaluable patients who achieved response in the mBCC cohort (a), those in the laBCC cohort with treatment duration > 20 months (b), and those in the laBCC cohort who were treated for < 20 months (c). laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.